The purpose of the study was to analyze the data of the domestic and foreign specialized literature, which are devoted to the pathogenesis, features of the topography, risk factors, prognosis of the course of bilateral synchronous and metachronous breast cancer. Materials and methods. Analytical and bibliosemantic methods were used in the research. The search for scientific information on bilateral synchronous and metachronous breast cancer for the period from 1990 to 2021 was conducted in databases of electronic searching systems. Results and discussion. Bilateral cancer can be either primary or metastatic to the contralateral breast. Primary one, depending on the time of tumor development in the contralateral breast gland, is divided into synchronous (development interval up to 6 months) and metachronous (development interval more than 6 months). Synchronous tumors of the breast glands are found significantly less frequently (22.7%) than metachronous tumors (69.6%). Relative risk factors for the occurrence of bilateral metachronous breast cancer are the presence of a BRCA1 and BRCA2 gene mutation, a heavy family history of breast cancer in blood relatives, and a young age of up to 45 years. A higher risk was established in patients with a lobular histological type of carcinoma compared to ductal carcinoma and with the absence of expression of steroid hormone receptors in the tumor. Bilateral synchronous tumors are very often characterized by the same visual manifestations during mammography, and their location in the breast glands is a "mirror image". Metachronous tumors are characterized by a smaller size, with rare involvement of axillary lymph nodes. A peculiarity of the topography of metachronous breast cancer is the presence, mainly in the upper outer quadrants of the breast gland, of a fixed or slow-moving nodule of rounded or star shape with unclear contours. Magnetic resonance mammography of the glands is an effective method of comprehensive diagnosis of breast pathology and is performed when other imaging methods are ineffective (sensitivity 99.2%, specificity 97.9%, accuracy 98.9%). The duration of the recurrence-free period in patients with synchronous tumor was 126.3 months, while in patients with metachronous tumor it was 243.7 months. Conclusion. The problem of bilateral breast cancer remains complex and far from fully understood. There are many controversial issues related to the pathogenesis, risk factors, features of the topography, clinical and morphological manifestations, diagnosis, recurrence-free and overall survival of bilateral breast carcinoma, which is important for determining and evaluating the prognosis, as well as the choice of management tactics for such patients

Keywords: bilateral breast cancer, etiology, pathogenesis, risk factors, clinical and morphological characteristics, prognosis

Full text: PDF (Ukr) 301K

1. WHO. Breast cancer. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer
2. Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami HO, et al. Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol. 2007;25(27):4210-4216. PMID: 17878475. doi: 10.1200/JCO.2006.10.5056
3. Verkooijen HM, Chatelain V, Fioretta G, Vlastos G, Rapiti E, Sappino AP, et al. Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Res Treat. 2007 Nov;105(3):347-57. PMID: 17186359. doi: 10.1007/s10549-006-9455-x
4. Ozturk A, Alco G, Sarsenov D, Ilgun S, Ordu C, Koksal U, et al. Synchronous and metachronous bilateral breast cancer: A long-term experience. J BUON. 2018 Nov-Dec;23(6):1591-1600. PMID: 30610782
5. Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999;8:855-861. PMID: 10548312
6. Bernstein JL, Lapinski RH, Thacore SS, Doucette JT, Thompson WD. The descriptive epidemiology of second primary breast cancer. Epidemiology. 2003;14:552-558. PMID: 14501270. doi: 10.1097/01.ede.0000072105.39021.6d
7. Carmichael AR, Bendall S, Lockerbie L, Prescott R, Bates T. The long-term outcome of synchronous bilateral breast cancer in worse than metachronous or unilateral tumours. Eur J Surg Oncol. 2002;28 388-391. PMID: 12099647. doi: 10.1053/ejso.2002.1266
8. Chaudary MA, Millis RR, Hoskins EO, Halder M, Bulbrook RD, Cuzick J, et al. Bilateral primary breast cancer: A prospective study of disease incidence. Br J Surg. 1984;71:711-4. PMID: 6478165. doi: 10.1002/bjs.1800710924
9. Lu W, Schaapveld M, Jansen L, Bagherzadegan E, Sahinovic MM, Baas PC, et al. The value of surveillance mammography of the contralateral breast in patients with a history of breast cancer. Eur J Cancer. 2009 Nov;45(17):3000-7. PMID: 19744851. doi: 10.1016/j.ejca.2009.08.007
10. Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011 Apr 26;104(9):1384-92. PMID: 21487411. PMCID: PMC3101934. doi: 10.1038/bjc.2011.120
11. Jobsen JJ, van der Palen J, Ong F, Riemersma S, Struikmans H. Bilateral breast cancer, synchronous and metachronous; differences and outcome. Breast Cancer Res Treat. 2015 Sep;153(2):277-83. PMID: 26268697. doi: 10.1007/s10549-015-3538-5
12. Roder D, de Silva P, Zorbas H, Kollias J, Malycha P, Pyke C, et al. Survival from synchronous bilateral breast cancer: the experience of surgeons participating in the breast audit of the Society of Breast Surgeons of Australia and New Zealand. Asian Pac J Cancer Prev. 2012;13(4):1413-8. PMID: 22799341. doi: 10.7314/apjcp.2012.13.4.1413
13. Xing Y, Meng Q, Sun L, Chen X, Cai L. Survival analysis of patients with unilateral and bilateral primary breast cancer in Northeast China. Breast Cancer. 2015 Sep;22(5):536-43. PMID: 24510639. doi: 10.1007/s12282-014-0517-3
14. Gollamudi SV, Gelman RS, Peiro G, Schneider LJ, Schnitt SJ, Recht A, et al. Breast-conserving therapy for stage I-II synchronous bilateral breast carcinoma. Cancer. 1997 Apr 1;79(7):1362-9. PMID: 9083159. doi: 10.1002/(SICI)1097-0142(19970401)79:7<1362::AID-CNCR14>3.0.CO;2-Y
15. Fritz AG, Ries L. The SEER Program Code Manual. 3rd ed.1998. Available from: https://seer.cancer.gov/archive/manuals/codeman.pdf
16. Schmid SM, Pfefferkorn C, Myrick ME, Viehl CT, Obermann E, Schötzau A, et al. Prognosis of early-stage synchronous bilateral invasive breast cancer. Eur J Surg Oncol. 2011 Jul;37(7):623-8. PMID: 21628090. doi: 10.1016/j.ejso.2011.05.006
17. Baykara M, Ozturk SC, Buyukberber S, Helvaci K, Ozdemir N, Alkis N, et al. Clinicopathological features in bilateral breast cancer. Asian Pac J Cancer Prev. 2012;13(9):4571-5. PMID: 23167382. doi: 10.7314/apjcp.2012.13.9.4571
18. Holm M, Tjønneland A, Balslev E, Kroman N. Prognosis of synchronous bilateral breast cancer: a review and meta-analysis of observational studies. Breast Cancer Res Treat. 2014 Aug;146(3):461-75. PMID: 25007962. doi: 10.1007/s10549-014-3045-0
19. Newman LA, Sahin AA, Cunningham JE, Bondy ML, Mirza NQ, Vlastos GS, et al. A case-control study of unilateral and bilateral breast carcinoma patients. Cancer. 2001 May 15;91(10):1845-53. Erratum in: Cancer. 2002 Feb 15;94(4):1191. PMID: 11346865. doi: 10.1002/1097-0142(20010515)91:10<1845::AID-CNCR1205>3.0.CO;2-Z
20. Wadasadawala T, Lewis S, Parmar V, Budrukkar A, Gupta S, Nair N, et al. Bilateral Breast Cancer After Multimodality Treatment: A Report of Clinical Outcomes in an Asian Population. Clin Breast Cancer. 2018 Aug;18(4): e727-e737. PMID: 29254601. doi: 10.1016/j.clbc.2017.11.003
21. Ibrahim NY, Sroor MY, Darwish DO. Impact of bilateral breast cancer on prognosis: synchronous versus metachronous tumors. Asian Pac J Cancer Prev. 2015;16(3):1007-10. PMID: 25735321. doi: 10.7314/APJCP.2015.16.3.1007
22. Liang X, Li D, Geng W, Cao X, Xiao C. The prognosis of synchronous and metachronous bilateral breast cancer in Chinese patients. Tumour Biol. 2013 Apr;34(2):995-1004. PMID: 23296702. doi: 10.1007/s13277-012-0636-4
23. Vuoto HD, García AM, Candás GB, Zimmermann AG, Uriburu JL, Isetta JA, et al. Bilateral breast carcinoma: clinical characteristics and its impact on survival. Breast. 2010 Nov-Dec;16(6):625-32. PMID: 21070440.
24. doi: 10.1111/j.1524-4741.2010.00976.x
25. Beckmann KR, Buckingham J, Craft P, Dahlstrom JE, Zhang Y, Roder D, et al. Clinical characteristics, and outcomes of bilateral breast cancer in an Australian cohort. Breast. 2011 Apr;20(2):158-64. PMID: 21093260. doi: 10.1016/j.breast.2010.10.004
26. Kuo WH, Yen AM, Lee PH, Chen KM, Wang J, Chang KJ, et al. Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. Br J Cancer. 2009 Feb 24;100(4):563-70. PMID: 19190627. PMCID: PMC2653740.
27. doi: 10.1038/sj.bjc.6604898
28. Holm M, Tjønneland A, Balslev E, Kroman N. Prognosis of synchronous bilateral breast cancer: a review and meta-analysis of observational studies. Breast Cancer Res Treat. 2014 Aug;146(3):461-75. PMID: 25007962. doi: 10.1007/s10549-014-3045-0
29. Quan G, Pommier SJ, Pommier RF. Incidence, and outcomes of contralateral breast cancers. Am J Surg. 2008;195(5):645-650; discussion 650. PMID: 18424281. doi: 10.1016/j.amjsurg.2008.01.007
30. Deo VS, Shridhar D, Shukla NK, Kumar S, Purkayastha J, Raina V, et al. Clinical profile and m anagement of bilateral breast cancer. Breast Cancer Res. 2005;7(Suppl 1):6-10. PMCID: PMC4231920. doi: 10.1186/bcr1240
31. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009 Feb;7(2):122-92. PMID: 19200416. doi: 10.6004/jnccn.2009.0012
32. Kerimov PA. Dvustoronnij rak molochnyh zhelez: osobennosti techeniya i rezul'taty terapii [Bilateral breast cancer: features of the course and results of therapy]. Mammologiya. 2005;(1):36-41. [Russian]
33. Biesheuvel S, Weigel S, Heindel W. Mammography Screening: Evidence, History and Current Practice in Germany and Other European Countries. Breast Care (Basel). 2011;6(2):104-109. PMID: 21673820. PMCID: PMC3104900. doi: 10.1159/000327493
34. Steven A. Narod. Bilateral breast cancer. Nat Rev Clin Oncol. 2014;11:157-166. PMID: 24492834. doi: 10.1038/nrclinonc.2014.3
35. Filyushkin IYu, Ivanov VM, Bujdenok YuM. Sinhronnyj rak molochnyh zhelez: klinika, diagnostika, lechenie, prognoz [Synchronous breast cancer: clinic, diagnosis, treatment, prognosis]. Opuholi zhenskoj reproduktivnoj sistemy. 2007;(4):14-6. [Russian]
36. Selezneva TD. Oshibki v diagnostike pervichnomnozhestvennyh sinhronnyh zlokachestvennyh novoobrazovanij molochnoj zhelezy. Rannyaya diagnostika I prichiny zapushchennosti opuholej osnovnyh lokalizacij [Errors in the diagnosis of primary multiple synchronous malignant neoplasms of the breast. Early diagnosis and causes of neglect of tumors of the main localizations]. Saratov: Izd-vo Sarat med un-ta; 2008. s. 84-93. [Russian]
37. Yadav ВS, Sharma SC, Patel FD, Ghoshal S, Kapoor RK. Second primary in the contralateral breast after treatment of breast cancer. Radiother Oncol. 2008;86(2):171-6. PMID: 17961777. doi: 10.1016/j.radonc.2007.10.002
38. Nsouli-Maktabi HH, Henson DE, Younes N, Young HA, Cleary SD. Second primary breast, endometrial, and ovarian cancers in Black and White breast cancer survivors over a 35-year time span: effect of age. Breast Cancer Res Treat. 2011 Oct;129(3):963-9. PMID: 21553293. doi: 10.1007/s10549-011-1560-9
39. Hemminki K, Vaittinen P. Risk factors and age-incidence relationships for contralateral breast cancer. Int J Cancer. 2000 Dec 15;88(6):998-1002. PMID: 11093827. doi: 10.1002/1097-0215(20001215)88:6<998::AID-IJC25>3.0.CO;2-0
40. Colorado Central Cancer Registry. Available from: https://cdphe.colorado.gov/center-for-health-and-environmental-data/registries-and-vital-statistics/colorado-central-cancer
41. Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):855-61. PMID: 10548312
42. Kheirelseid EA, Jumustafa H, Miller N, Curran C, Sweeney K, Malone C, et al. Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics. Breast Cancer Res Treat. 2011 Feb;126(1):131-40. PMID: 20665107. doi: 10.1007/s10549-010-1057-y
43. Senkus E, Szade J, Pieczyńska B, Zaczek A, Pikiel J, Sosińska-Mielcarek K, et al. Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype. Int J Clin Exp Pathol. 2013 Dec 15;7(1):353-63. PMID: 24427357. PMCID: PMC3885491
44. Ibrahim NY, Sroor MY, Darwish DO. Impact of bilateral breast cancer on prognosis: synchronous versus metachronous tumors. Asian Pac J Cancer Prev. 2015;16(3):1007-10. PMID: 25735321. doi: 10.7314/APJCP.2015.16.3.1007
45. Vaittinen P, Hemminki K. Risk factors and age-incidence relationships for contralateral breast cancer. Int J Cancer. 2000 Dec 15;88(6):998-1002. PMID: 11093827. doi: 10.1002/1097-0215(20001215)88:6<998::AID-IJC25>3.0.CO;2-0
46. Sandberg ME, Hall P, Hartman M, Johansson AL, Eloranta S, Ploner A, et al. Estrogen receptor status in relation to risk of contralateral breast cancer-a population-based cohort study. PLoS One. 2012;7(10): e46535. PMID: 23056335. PMCID: PMC3466301. doi: 10.1371/journal.pone.0046535
47. Wang T, Liu H, Chen KX, Xun P, Li HX, Tang SC. The risk factors and prognosis of bilateral primary breast cancer: a comparative study with unilateral breast cancer. Oncol Res. 2011;19(3-4):171-8. PMID: 21473293. doi: 10.3727/096504011X12935427587966
48. Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst. 2009 Aug 5;101(15):1058-65. PMID: 19590058. PMCID: PMC2720990. doi: 10.1093/jnci/djp181
49. Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010 May 10;28(14):2404-10. PMID: 20368571. PMCID: PMC2881721. doi: 10.1200/JCO.2009.24.2495
50. Intra M, Rotmensz N, Viale G, Mariani L, Bonanni B, Mastropasqua MG, et al. Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. Cancer. 2004 Sep 1;101(5):905-12. PMID: 15329896. doi: 10.1002/cncr.20452
51. Wadasadawala T, Lewis S, Parmar V, Budrukkar A, Gupta S, Nair N, et al. Bilateral Breast Cancer After Multimodality Treatment: A Report of Clinical Outcomes in an Asian Population. Clin Breast Cancer. 2018 Aug;18(4): e727-e737. PMID: 29254601. doi: 10.1016/j.clbc.2017.11.003
52. Sas-Korczyńska B, Kamzol W, Kołodziej-Rzepa M, Jerzy W. Mituś, Wojciech M. Wysocki. The characteristics of bilateral breast cancer patients. Nowotwory J Oncol. 2018;5-6(68):221-226. doi: 10.5603/NJO.2018.0035
53. Kerimov RA. Dvustoronnij rak molochnyh zhelez: osobennosti techeniya i rezul'taty terapii [Bilateral breast cancer: features of the course and results of therapy]. Mammologiya. 2005;(1):36-41. [Russian]
54. Singla A, Kaur N, Walia DS, Singla D. Bilateral Metachronous Breast Carcinoma: A Rare Case Report. Int J Appl Basic Med Res. 2018 Apr-Jun;8(2):126-128. PMID: 29744328. PMCID: PMC5932922. doi: 10.4103/ijabmr.IJABMR_384_16
55. Vichapat V, Garmo H, Holmberg L, Fentiman IS, Tutt A, Gillett C, et al. Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses. Breast Cancer Res Treat. 2011 Nov;130(2):609-18. PMID: 21671018. doi: 10.1007/s10549-011-1618-8
56. Steinmann D, Bremer M, Rades D, Skawran B, Siebrands C, Karstens JH, et al. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. Br J Cancer. 2001 Sep 14;85(6):850-8. PMID: 11556836. PMCID: PMC2375067. doi: 10.1054/bjoc.2001.2016
57. Hartman M, Czene K, Reilly M, Bergh J, Lagiou P, Trichopoulos D, et al. Genetic implications of bilateral breast cancer: a population based cohort study. Lancet Oncol. 2005 Jun;6(6):377-82. PMID: 15925815. doi: 10.1016/S1470-2045(05)70174-1
58. Gollamudi SV, Gelman RS, Peiro G, Schneider LJ, Schnitt SJ, Recht A, et al. Breast-conserving therapy for stage I-II synchronous bilateral breast carcinoma. Cancer. 1997 Apr 1;79(7):1362-9. PMID: 9083159. doi: 10.1002/(SICI)1097-0142(19970401)79:7<1362::AID-CNCR14>3.0.CO;2-Y
59. Newman LA, Sahin AA, Cunningham JE, Bondy ML, Mirza NQ, Vlastos GS, et al. A case-control study of unilateral and bilateral breast carcinoma patients. Cancer. 2001 May 15;91(10):1845-53. Erratum in: Cancer 2002 Feb 15;94(4):1191. PMID: 11346865. doi: 10.1002/1097-0142(20010515)91:10<1845::AID-CNCR1205>3.0.CO;2-Z
60. Heaton KM, Peoples GE, Singletary SE, Feig BW, Ross MI, Ames FC, et al. Feasibility of breast conservation therapy in metachronous or synchronous bilateral breast cancer. Ann Surg Oncol. 1999 Jan-Feb;6(1):102-8. PMID: 10030422. doi: 10.1007/s10434-999-0102-8
61. Sim Y, Tan VKM, Sidek NAB, Chia DKA, Tan BKT, Madhukumar P, et al. Bilateral breast cancers in an Asian population, and a comparison between synchronous and metachronous tumours. ANZ J Surg. 2018 Oct;88(10):982-987. PMID: 30141242. doi: 10.1111/ans.14773
62. Dawson PJ, Maloney T, Gimotty P, Juneau P, Ownby H, Wolman SR. Bilateral breast cancer: one disease or two? Breast Cancer Res Treat. 1991 Nov;19(3):233-44. PMID: 1663803. doi: 10.1007/BF01961160
63. Singla A, Kaur N, Walia DS, Singla D. Bilateral Metachronous Breast Carcinoma: A Rare Case Report. Int J Appl Basic Med Res. 2018 Apr-Jun;8(2):126-128. PMID: 29744328. PMCID: PMC5932922. doi: 10.4103/ijabmr.IJABMR_384_16
64. Senkus E, Szade J, Pieczyńska B, Zaczek A, Pikiel J, Sosińska-Mielcarek K, et al. Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype. Int J Clin Exp Pathol. 2013 Dec 15;7(1):353-63. PMID: 24427357. PMCID: PMC3885491
65. Ibrahim NY, Sroor MY, Darwish DO. Impact of bilateral breast cancer on prognosis: synchronous versus metachronous tumors. Asian Pac J Cancer Prev. 2015;16(3):1007-10. PMID: 25735321. doi: 10.7314/APJCP.2015.16.3.1007
66. Howe HL, Weinstein R, Alvi R, Kohler B, Ellison JH. Women with multiple primary breast cancers diagnosed within a five year period, 1994-1998. Breast Cancer Res Treat. 2005 Apr;90(3):223-32. PMID: 15830135. doi: 10.1007/s10549-004-4258-4
67. Anderson DE. Genetic study of breast cancer: identification of a high risk group. Cancer. 1974 Oct;34(4):1090-7. PMID: 4424650. doi: 10.1002/1097-0142(197410)34:4<1090::AID-CNCR2820340419>3.0.CO;2-J
68. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004 Jun 15;22(12):2328-35. PMID: 15197194. doi: 10.1200/JCO.2004.04.033
69. Verhoog LC, Brekelmans CT, Seynaeve C, Meijers-Heijboer EJ, Klijn JG. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer. 2000 Aug;83(3):384-6. PMID: 10917555. PMCID: PMC2374577. doi: 10.1054/bjoc.2000.1239
70. Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011;104(9):1384-1392. PMID: 21487411. PMCID: PMC3101934. doi: 10.1038/bjc.2011.120
71. Narod SA. Bilateral breast cancers. Nat Rev Clin Oncol. 2014;11(3):157-166. PMID: 24492834. doi: 10.1038/nrclinonc.2014.3
72. Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27(35):5887-5892. PMID: 19858402. doi: 10.1200/JCO.2008.19.9430
73. Fowble B, Hanlon A, Freedman G, Nicolaou N, Anderson P. Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk. Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):679-90. PMID: 11597809. doi: 10.1016/S0360-3016(01)01665-0
74. Bergthorsson JT, Ejlertsen B, Olsen JH, Borg A, Nielsen KV, Barkardottir RB, et al. BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age. J Med Genet. 2001 Jun;38(6):361-8. PMID: 11389159; PMCID: PMC1734886. doi: 10.1136/jmg.38.6.361
75. Eliyatkin N, Zengel B, Yagci A, Comut E, Postaci H, Uslu A, et al. Properties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up. Asian Pac J Cancer Prev. 2015;16(12):4921-6. PMID: 26163616. doi: 10.7314/APJCP.2015.16.12.4921
76. Heron DE, Komarnicky LT, Hyslop T, Schwartz GF, Mansfield CM. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer. 2000;88:2739-2750. PMID: 10870056. doi: 10.1002/1097-0142(20000615)88:12<2739::AID-CNCR12>3.0.CO;2-J
77. Baretta Z, Olopade OI, Huo D. Heterogeneity in hormone-receptor status and survival outcomes among women with synchronous and metachronous bilateral breast cancers. Breast. 2015;24:131-6. PMID: 25534718. PMCID: PMC4375038. doi: 10.1016/j.breast.2014.12.001
78. Zhi H, Ou B, Luo BM, Feng X, Wen YL, Yang HY. Comparison of ultrasound elastography, mammography, and sonography in the diagnosis of solid breast lesions. J Ultrasound Med. 2007;26(6):807-15. PMID: 17526612. doi: 10.7863/jum.2007.26.6.807
79. Murphy TJ, Conant EF, Hanau CA, Ehrlich SM, Feig SA. Bilateral Breast Carcinoma: Mammographic and Histologic Correlation. Radiology. 1995;195:617-621. PMID: 7753983. doi: 10.1148/radiology.195.3.7753983
80. Leis HP Jr, Mersheimer WL, Black MM, De Chabon A. The second breast. NY State Med. 1965;65:2460-2468.
81. Senofsky GM, Wanebo HJ, Wilhelm MC, Pope TL Jr, Fechner RE, Broaddus W, et al. Has monitoring of the contralateral breast improved the prognosis in patients treated for primary breast cancer? Cancer. 1986;57:597-602. PMID: 3942996. doi: 10.1002/1097-0142(19860201)57:3<597::AID-CNCR2820570334>3.0.CO;2-5
82. Roubidoux MA, Lai NE, Paramagul C, Joynt LK, Helvie MA. Mammographic appearance of cancer in the opposite breast: comparison with the first cancer. AJR Am J Roentgenol. 1996 Jan;166(1):29-31. PMID: 8571898. doi: 10.2214/ajr.166.1.8571898
83. Lou L, Cong XL, Yu GF, Li JC, Ma YX. US findings of bilateral primary breast cancer: retrospective study. Eur J Radiol. 2007 Jan;61(1):154-7. PMID: 17064869. doi: 10.1016/j.ejrad.2006.08.022
84. Kim MJ, Kim EK, Kwak JY, Park BW, Kim SI, Sohn J, et al. Role of sonography in the detection of contralateral metachronous breast cancer in an Asian population. AJR Am J Roentgenol. 2008 Feb;190(2):476-80. PMID: 18212235. doi: 10.2214/AJR.07.2683
85. Jacobs MA, Barker PB, Bottomley PA, Bhujwalla Z, Bluemke DA. Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J Magn Reson Imaging. 2004;19(1):68-75. PMID: 14696222. doi: 10.1002/jmri.10427
86. Derebek E, Balci P, Alanyali H, Kocdor MA, Capa G, Gorken IB, et al. Detection of bilateral multifocal breast cancer using Tc-99m sestamibi imaging. The role of delayed imaging. Clin Nucl Med. 1999;24:590-3. PMID: 10439180. doi: 10.1097/00003072-199908000-00009
87. Meladze NV, Shariya MA, Ustyuzhanin DV, Ternovoy SK. The role of Magnetic Resonance Mammography аnd Magnetic Resonance Spectroscopy іn the differential diagnosis of breast tumors. J Radiol Nucl Med. 2018;99(1):13-22. doi: 10.20862/0042-4676-2018-99-1-13-22